SIMONA FIKHMAN: Open Payments
NPI 1477979656 · STUDIO CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,905 in 76 payments from 20 companies in 2025. Trend: 2023 $2,785 · 2024 $2,278 · 2025 $1,905
Food & beverage: $1,905
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $277 |
| LEO Pharma Inc. | 12 | $227 |
| GENZYME CORPORATION | 5 | $193 |
| ABBVIE INC. | 16 | $190 |
| Regeneron Healthcare Solutions, Inc. | 4 | $184 |
| Lilly USA, LLC | 3 | $151 |
| Organon LLC | 1 | $140 |
| Incyte Corporation | 5 | $122 |
| UCB, Inc. | 2 | $65 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $57 |
Products named: DUPIXENT, Rhapsido, ADBRY, VTAMA, EBGLYSS, OPZELURA, COSENTYX, RINVOQ.
Industry payments across CA — which companies pay providers there.
